Clinical Trial Update: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of ONS-5010 in neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration
• Wet Macular Degeneration

Drugs mentioned

• ONS-5010

Snippet

Sponsor: Outlook Therapeutics, Inc. | Conditions: Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED